“Mesalamine is a difficult to make product with a limited number of suppliers, and this approval highlights the strength of our R&D capabilities. Additionally, the approval of lenalidomide represents ...

H.C. Wainwright updated AnaptysBio’s model to include $75M in milestones from GSK to the company in 2026 for $1B in annual sales of Jemperli. In addition, it increased estimates for ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...

LAHORE: The Punjab government announced on Friday that those seeking assistance under the Nighaban Ramazan package should get themselves registered by Feb 15. It also announced that registration ...

DAVOS, Switzerland, Jan 24 (Reuters) - Saudi Economy Minister Faisal Alibrahim said on Friday that the kingdom's $600 billion expanded package with the United States includes investments as well ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or ...

The Jemperli Dostarlimab market size has brought about notable growth and shifts in recent years. With a history of significant compound annual growth rate HCAGR, the ...

Teva Pharmaceutical Industries Ltd. ADR-0.93% $19.32B ...